Market notice 189/21 – Follicum is moved to the Observation List
Follicum AB on schedule to present top-line results from the phase IIa study with FOL-005 for hair growth at the end of October
Follicum AB reports top-line data from First-in-Man Scalp Study with FOL-005 against hair loss
glucotox eng - Follicum
What Hair Loss Treatments Could Look Like in the Future | Allure
Follicum
182/18 – Last day of trading in Follicum AB's BTU
Om Spotlight Follicum AB will be transferred to Spotlight Stock Market's observation list About Spotlight
Follicum successfully completes toxicology studies for upcoming FOL-005 Phase IIa clinical trial in patients with hair loss
Follicum (FOLLI) aktie | Videos - Börskollen
Female alopecia – new solutions on the horizon - BioStock
Lund University research group receives follow-on DKK 1 million grant from Novo Nordisk Foundation for diabetes-related studies
Follicum receives European patent for the company's peptides for developing first in class diabetes treatments
Follicum receives grant of a patent in the U.S. for extended protection of the product candidate FOL-005
Follicum applies for extended patent for its topical formulation - BioStock
Follicum applies for extended patent for its topical formulation - BioStock
Interview with Alejandra Mørk, new Member of the Board in Follicum
Follicum appoints new CEO and establishes new role as Chief Scientific Officer
Market Notice 11/22 – Follicum AB will be delisted after close of the market on February 3, 2022
Is the Age-Old Quest for a Baldness Cure Reaching Its End? | The New Yorker
150/19 – Information regarding the rights issue from Follicum AB
Follicum finalises patient recruitment in hair growth study - BioStock
Follicum re-starts phase II study with FOL-005 for stimulation of hair growth and expands the number of study centres
Follicum files international patent application conferring extended protection for the topical formulation of FOL-005 and other
